# Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

Source: https://onco.cc/trials/nct07024706/  
OnCo record `nct07024706` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Acalabrutinib and Venetoclax in chronic lymphocytic leukaemia, run by AstraZeneca, now recruiting.

## Summary

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab is a phase 2 interventional study registered as NCT07024706 by AstraZeneca, with 80 participants planned, started 2026-06-04 and due to reach its primary completion in 2029-05-01. Interventions recorded: Acalabrutinib and Venetoclax.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07024706
- Phase: 2
- Setting: The MAVRiC Study: A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL/SLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab
- Sponsor: AstraZeneca
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07024706: https://clinicaltrials.gov/study/NCT07024706

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Acalabrutinib](https://onco.cc/drugs/acalabrutinib/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/), [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct07024706.json